- Report
- April 2025
- 50 Pages
Global
From €2502EUR$2,650USD£2,146GBP
Hexoprenaline is a bronchodilator drug used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is a beta-2 agonist, meaning it works by stimulating the beta-2 receptors in the lungs, causing them to relax and open up the airways. Hexoprenaline is available in both oral and inhaled forms, and is often used in combination with other drugs to provide better relief from symptoms.
The hexoprenaline market is a growing segment of the respiratory drugs market, with increasing demand for the drug due to its effectiveness in treating respiratory diseases. Hexoprenaline is also used in the treatment of cystic fibrosis, and is increasingly being used in combination with other drugs to provide better relief from symptoms.
Some of the major companies in the hexoprenaline market include GlaxoSmithKline, Merck, Pfizer, AstraZeneca, and Novartis. Show Less Read more